D. Ross Camidge, MD, PhD
The use of single-agent immunotherapy and chemoimmunotherapy in patients with both nonsquamous and squamous non–small cell lung cancer (NSCLC) has been addressed in several clinical trials. However, the decision of whether to use a monotherapy or combination approach requires further investigation, said D. Ross Camidge, MD, PhD.
State of the Science Summit™ on Advanced Non–Small Cell Lung Cancer, Camidge, professor, Division of Medical Oncology, Joyce Zeff Chair in Lung Cancer Research, School of Medicine, Division of Medical Oncology, University of Colorado, discussed the use of immunotherapy in patients with NSCLC.
OncLive: Can everyone with NSCLC benefit from immunotherapy?
We’re entering a renaissance in terms of immunotherapy for NSCLC. This is not necessarily just because we have these drugs, but we have a better understanding that they don’t work in everybody and [of] how we should use them. The whole “battleground” has moved to the first-line setting. We have the idea that by enriching for PD-L1, we can give pembrolizumab monotherapy. That was the KEYNOTE-024 study. In that study, enrichment meant a tumor proportion score (TPS) of 50% or greater, which is about 30% of lung cancer across all histologies.
... to read the full story